Recent Advances in CAR T-Cell Therapy in Lymphoma: Insights from Experts at The John Theurer Cancer Center : Episode 3
CAR-T therapy in Second-Line Setting in LBCL
Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.
EP: 1.Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL
EP: 2.Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL
Now Viewing
EP: 3.CAR-T therapy in Second-Line Setting in LBCL
EP: 4.Managing Toxicities Associated with CAR-T Therapy in LBCL
EP: 5.Brexucabtagene Autoleucel in Mantle Cell Lymphoma
EP: 6.CAR-T Therapies in the Follicular Lymphoma Treatment Landscape
EP: 7.Role of CAR-T Therapies in Acute Lymphoblastic Lymphoma
EP: 8.Recent Updates on CAR-T Therapies in Chronic Lymphocytic Leukemia
EP: 9.Next Generation of CAR-T Therapies in Lymphoma
EP: 10.Future Perspectives on CAR-T Therapies in Lymphoma
EP: 11.Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma
Recent Videos
Related Content
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)
May 14th 2025Article
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025Podcast
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
